These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20657889)

  • 1. [Anabolic therapy of induced osteoporosis in beta-thalassaemia major: case report and literature review].
    Trotta A; Corrado A; Cantatore FP
    Reumatismo; 2010; 62(2):119-26. PubMed ID: 20657889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anabolic treatment for osteoporosis: PTH treatment].
    Kaji H; Sugimoto T
    Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of PTH in the treatment of osteoporosis.
    Borba VZ; Mañas NC
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alendronate for treatment of osteoporoses].
    Harada A
    Nihon Rinsho; 2009 May; 67(5):943-7. PubMed ID: 19432114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Very old patients with osteoporosis should be treated with alendronate].
    Shiraki M
    Nihon Ronen Igakkai Zasshi; 2006 Jul; 43(4):455-8. PubMed ID: 16937932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of teriparatide retreatment in a patient with β-thalassemia major.
    Tournis S; Dede AD; Savvidis C; Triantafyllopoulos IK; Kattamis A; Papaioannou N
    Transfusion; 2015 Dec; 55(12):2905-10. PubMed ID: 26174236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
    N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Osteoporosis: Optimizing treatment strategy].
    Thomas T
    Presse Med; 2006 Oct; 35(10 Pt 2):1543-6. PubMed ID: 17028519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate.
    Schneider JP
    Geriatrics; 2006 Jan; 61(1):31-3. PubMed ID: 16405362
    [No Abstract]   [Full Text] [Related]  

  • 13. Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
    Shimon I; Eshed V; Doolman R; Sela BA; Karasik A; Vered I
    Osteoporos Int; 2005 Dec; 16(12):1591-6. PubMed ID: 16362147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug therapy of secondary osteoporosis: glucocorticoid-induced osteoporosis].
    Soen S
    Nihon Rinsho; 2009 May; 67(5):985-90. PubMed ID: 19432121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current research in adequate treatment by Osteoporosis Research Group].
    Orimo H; Miyakawa N; Kuroda T
    Clin Calcium; 2006 Sep; 16(9):1500-7. PubMed ID: 16951475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density.
    Khan A; Dubois S; Khan AA; Zohair Rahman M; Ahmed Khan O; Syed HT; Derzko C
    J Obstet Gynaecol Can; 2014 Nov; 36(11):976-982. PubMed ID: 25574674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates in the treatment of thalassemia-induced osteoporosis.
    Morabito N; Lasco A; Gaudio A; Crisafulli A; Di Pietro C; Meo A; Frisina N
    Osteoporos Int; 2002 Aug; 13(8):644-9. PubMed ID: 12181623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance.
    Pepe J; Petrucci MT; Mascia ML; Piemonte S; Fassino V; Romagnoli E; Minisola S
    Calcif Tissue Int; 2008 Jun; 82(6):418-26. PubMed ID: 18528609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.